Icosapent Ethyl Modestly Impacts Various Biomarkers Linked W
Serum levels of interleukin-1, interleukin-6, high-sensitivity CRP, oxidized LDL cholesterol, homocysteine, lipoprotein(a), and lipoprotein-associated phospholipase A2 (Lp-PLA2) were measured at baseline, at 12 months, at 24 months, and at the end-of-study visit among REDUCE-IT participants with triglyceride levels >135 mg/dL and <500 mg/dL who were randomly allocated to treatment with either 4 grams daily of icosapent ethyl or mineral oil used as a comparator. The levels of biomarkers associated with atherosclerosis increased over time. At study conclusion, between-group treatment differences largely reflected increases in the mineral oil group with median percent differences of 2.4% for lipoprotein(a), 3.0% for homocysteine, 4.2% for oxidized LDL cholesterol, 19.8% for interleukin-6, 26.2% for Lp-PLA2, 38.5% for high-sensitivity CRP, and 48.7% for interleukin-1 (all P values <0.007). These data are consistent with previous REDUCE-IT results in which the median percent change for LDL cholesterol at 12 months was 1.2% among those allocated to icosapent ethyl and 10.9% among those allocated to the mineral oil comparator.

Source: https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.122.059410